An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Study Type
OBSERVATIONAL
Enrollment
100
Groupe hospitalier sud
Amiens, France
NOT_YET_RECRUITINGOverall survival by 12 months
Time frame: 12 months
overal survival by 36 months
Time frame: 36 months
proportion of complete remission
Time frame: 36 months
the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood
Time frame: 36 months
the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood
Time frame: 36 months
Event free survival
Time frame: 36 months
Relapse free survival
Time frame: 36 months
the incidence ofBCR..ABL1 TK mutations
Time frame: 36 months
treatment tolerance
Time frame: 36 months
Death during induction
Time frame: 2 months
Death in complete remission
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Angers
Angers, France
NOT_YET_RECRUITINGCH de la cote basque
Bayonne, France
NOT_YET_RECRUITINGCHU Bordeaux
Bordeaux, France
RECRUITINGHopital Militaire Percy
Clamart, France
NOT_YET_RECRUITINGCHU clermont ferrand
Clermont-Ferrand, France
RECRUITINGCentre Hospitalier sud francilien
Corbeil-Essonnes, France
RECRUITINGCHU de grenoble
Grenoble, France
NOT_YET_RECRUITINGCHU Sud Réunion
La Réunion, France
NOT_YET_RECRUITINGCH Versailles
Le Chesnay, France
RECRUITING...and 13 more locations